Key facts
- Notable investors include Denkapparat.
- Status: Privately Held (backing).
Investors
1- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for ASH (Biotechnology)
- ·The full record, as it builds
Funding rounds
No funding rounds for ASH (Biotechnology) are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About ASH (Biotechnology)
Developer of therapies designed to refine immune responses and treat immune-related conditions ranging from allergies to severe diseases like graft-versus-host disease. The company's technology addresses a spectrum of immune system imbalances, from mild conditions such as allergies, where an overactive immune response to harmless substances causes inflammation and symptoms, to severe disorders that can result in significant morbidity and mortality, and it develops innovative therapies designed to modulate and restore immune system balance, enabling patients suffering from immune-mediated diseases to improve outcomes.
- Sector
- Healthcare
- HQ
- Berlin, Germany
- Founded
- 2014
- Employees
- 4
- Website
- ash-therapeutics.com/en
- Ownership
- Privately Held (backing)
ASH (Biotechnology) doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in ASH (Biotechnology) shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on ASH (Biotechnology) in its N-PORT filings yet. We sweep new filings monthly.